Potential of Florbetapir F 18 PET to Inform Clinical Diagnosis and Management of Patients With Progressive Cognitive Decline

PHASE3CompletedINTERVENTIONAL
Enrollment

239

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

July 31, 2012

Study Completion Date

July 31, 2012

Conditions
Progressive Cognitive Decline
Interventions
DRUG

florbetapir F 18

IV injection, 370 megabecquerel (MBq) (10 millicurie \[mCi\]), single dose

Trial Locations (18)

10021

Research Site, New York

11772

Research Site, Patchogue

27401

Research Site, Greensboro

27705

Research Site, Durham

33407

Research Site, West Palm Beach

33486

Research Site, Boynton Beach

33756

Research Site, Clearwater

33912

Research Site, Fort Myers

71130

Research Site, Shreveport

77042

Research Site, Houston

80304

Research Site, Boulder

85006

Research Site, Phoenix

85351

Research Site, Sun City

89121

Research Site, Las Vegas

94109

Research Site, San Francisco

02169

Research Site, Quincy

02903

Research Site, Providence

02906

Research Site, Providence

Sponsors
All Listed Sponsors
lead

Avid Radiopharmaceuticals

INDUSTRY